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The goal of this study was to compare the effects of two inflammatory modulators,
erythropoietin (EPO) and anakinra, on functional recovery and brain gene expression
following a cortical contusion impact (CCI) injury. Dosage regimens were designed
to provide serum concentrations in the range obtained with clinically approved
doses. Functional recovery was assessed using both motor and spatial learning
tasks and neuropathological measurements conducted in the cortex and hippocampus.
Microarray-based transcriptional profiling was used to determine the effect on gene
expression at 24 h, 72 h, and 7 days post-CCI. Ingenuity Pathway Analysis was used to
evaluate the effect on relevant functional categories. EPO and anakinra treatment resulted
in significant changes in brain gene expression in the CCI model demonstrating acceptable
brain penetration. At all three time points, EPO treatment resulted in significantly more
differentially expressed genes than anakinra. For anakinra at 24 h and EPO at 24 h,
72 h, and 7 days, the genes in the top 3 functional categories were involved in cellular
movement, inflammatory response and cell-to-cell signaling. For EPO, the majority of the
genes in the top 10 canonical pathways identified were associated with inflammatory
and immune signaling processes. This was true for anakinra only at 24 h post-traumatic
brain injury (TBI). The immunomodulation effects of EPO and anakinra did not translate
into positive effects on functional behavioral and lesion studies. Treatment with either
EPO or anakinra failed to induce significant beneficial effects on recovery of function or
produce any significant effects on the prevention of injury induced tissue loss at 30 days
post-injury. In conclusion, treatment with EPO or anakinra resulted in significant effects
on gene expression in the brain without affecting functional outcome. This suggests
that targeting these inflammatory processes alone may not be sufficient for preventing
secondary injuries after TBI.
Keywords: traumatic brain injury, recovery of function, cortical contusion impact, gene expression, erythropoietin,
anakinra
INTRODUCTION
Traumatic brain injury (TBI) is among the leading causes of
acute and chronic disability in the United States. Out of the 1.7
million Americans that endure a TBI each year, over 50,000 die
(Faul et al., 2010), making recovery of function a major pub-
lic health issue. The first or primary injury relates to the initial
injury caused by direct damage to the brain and only injury
prevention will reduce the consequences of the primary injury.
The second is indirect and progressive and is referred to as sec-
ondary injury. The etiology of the secondary cascade resulting
from TBI is likely due to interrelated processes including mito-
chondrial energy failure, excessive generation of reactive oxygen
species, activation of destructive enzymes, membrane disrup-
tion, neuronal death, thrombosis due to intravascular coagulation
in small vessels, increased synaptic concentrations of excitatory
amino acids, and activation of innate inflammatory responses
(Wang et al., 2006; Jennings et al., 2008; McConeghy et al.,
2012). Preventing the inflammatory response is considered a high
potential target for neuroprotection after TBI (Schouten, 2007;
Jennings et al., 2008). During secondary injury, early inflamma-
tion is triggered by multiple complex signals including, intracel-
lular signaling, reactive oxygen and nitrogen species and loss of
cellular homeostasis, all of which is mediated by microglia and
astrocytes (Mathew et al., 1994; Juliet et al., 2008; Rock and Kono,
2008). An increase in the brain and cerebral spinal fluid pro-
inflammatory cytokines [tumor necrosis factorα (TNFα), inter-
leukin (IL)-1β, IL-6], and anti-inflammatory cytokines [trans-
forming growth factor (TGF-β, IL-4, IL-10)] occurs after injury
in experimental TBI models and in patients with TBI (Morganti-
Kossmann et al., 2001). Although the precise mechanisms are
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unknown, the immune response following inflammation directly
induces apoptotic death and indirectly increases cell death by
signaling cellular death programs (Shojo et al., 2010; Das et al.,
2011).
The IL-1 family is a group of cytokines that are important for
initiating and regulating immune and inflammatory responses.
Animal models suggest that increasing levels of IL-1α and IL-1β
exacerbate brain damage, while administering an IL 1 receptor
antagonist (IL-1ra) reduces the infarct and improves recovery of
function (Feurstein et al., 1997; Touzani et al., 1999). IL-1ra is
a protein that in humans is encoded by the IL1RN gene and
in rodent by the IL-1rn gene. Preventing IL-1 from binding to
the IL-1 type receptor reduces inflammation (Feurstein et al.,
1997; Touzani et al., 1999; So et al., 2007). There have been
several experiments examining the role of IL-1ra in injury mod-
els other than ischemia, including subarachnoid hemorrhage,
cryogenic injury, and excitotoxic injury. Following injury, IL-
1ra reduced the number of nitric oxide synthase positive cells
and improved both anatomical and functional outcomes (Jones
et al., 2005). Elevation of IL-1ra after initiation of the inflam-
matory response is an important part of the auto-regulatory
network controlling the inflammatory response (Bartfai et al.,
2007). In patients with TBI, high concentrations of IL-1ra and
high ratio of IL-1ra/IL-1β were association with better outcome
(Hutchinson et al., 2007). IL-1ra reduces susceptibility to exci-
totoxic brain injury (Hagan et al., 1996), mediates convulsant
actions of seizures in transgenic mice (Vezzani et al., 2004)
and reduces damage following excitotoxic injury by attenuating
neuronal insult and microglial activation in hippocampal slice
cultures (Hailer et al., 2005) and in rodent models (Relton and
Rothwell, 1992).
Altering this inflammatory pathway, preventing or reducing
the inflammatory signal with an IL-1ra following TBI is a promis-
ing strategy in limiting the secondary injury. Erythropoietin
(epoetin alfa; EPO) and anakinra, a recombinant form of non-
glycosylated human IL-1 receptor antagonist are inflammatory
modulators proposed as promising neuroprotective agents for the
treatment of TBI. EPO, a hematopoietic growth factor that reg-
ulates red blood cell production also has significant pleiotropic
effects (Boogaerts, 2006; Mammis et al., 2009). EPO has been
shown to provide protection in a variety of models of neural dam-
age, including focal ischemic stroke, experimental autoimmune
encephalomyelitis, chemically-induced seizures, and blunt force
trauma (Brines et al., 2000; Cerami et al., 2002). Subsequent stud-
ies have established beneficial effects of EPO administration on
behavioral recovery from TBI (Brines et al., 2000; Cerami et al.,
2002; Meng et al., 2011). EPO administration has been found to
improve motor (Zhang et al., 2009), sensory (Xiong et al., 2008;
Zhang et al., 2009), and cognitive function in experimental TBI
(Lu et al., 2005; Yatsiv et al., 2005; Mahmood et al., 2007; Xiong
et al., 2008; Zhang et al., 2009; Meng et al., 2011) and has also
been shown to reduce lesion size (Xiong et al., 2008) and cell
death after injury (Yatsiv et al., 2005; Zhang et al., 2009; Meng
et al., 2011). Proposed mechanisms for the neuroprotective effect
have included the ability of EPO to protect nerve cells from glu-
tamate toxicity, reduce the immune response and inflammatory
reaction, enhance nerve recovery, play a role in neurogenesis,
prevent neuronal apoptosis, inhibit nitric oxide formation, and
prevent oxidative stress (for a review, see Mammis et al., 2009).
Research has shown that EPO can cross the blood brain barrier
and affect neural tissues, increasing oxygenation to vulnerable
tissues (Brines et al., 2000).
There is limited pre-clinical research evaluating treatment with
IL-1ra in attenuating neuronal injury. IL-1ra has been shown to
be a potential neuroprotective treatment in experimental stud-
ies in hippocampal slice cultures after excitotoxic damage (Hailer
et al., 2005), in models of focal cerebral ischemia (Relton et al.,
1996; Loddick et al., 1997), and in a fluid percussion brain
injury model (Toulmond and Rothwell, 1995; Relton et al., 1996;
Loddick et al., 1997; Lawrence et al., 1998; Sanderson et al., 1999;
Hailer et al., 2005).
The objective of this study was to compare the effects of
two inflammatory modulators, EPO and anakinra on functional
recovery and gene expression following a unilateral controlled
cortical impact (CCI) injury. This study is part of a project that
assesses the effectiveness of several drugs on TBI and to identify
the mechanism of action using microarray analysis. The ultimate
goal is to use these data to design a multi-drug treatment therapy
that will also be tested in our TBI model.
Prior to the CCI studies, single- and multiple-dose phar-
macokinetic studies were performed in uninjured animals to
determine the dose regimens needed to provide average serum
concentrations in the range of the concentrations obtained clini-
cally with FDA approved doses.
EXPERIMENTAL PROCEDURES
ANIMALS AND HOUSING
Male, Sprague-Dawley rats (Harlan, Indianapolis, IN) approx-
imately 3.5 months of age (mean body weight 350 g) were
used in this study. All animal and surgical procedures were
adhered to as described in the NIH Guide for the Care and
Use of Laboratory Animals. The Southern Illinois University
Institutional Animal Care and Use Committee (IACUC) and the
University of Washington’s IACUC reviewed and approved all
experimental procedures. Animals were housed in a university-
maintained, Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) accredited vivarium, with
a 12-h light/dark schedule and a controlled environmental tem-
perature of 22◦C in standard housing cages with food and water
available ad libitum.
PHARMACOKINETIC STUDIES
Male Sprague-Dawley rats with surgically implanted jugular vein
catheters were obtained from Harlan Laboratories. For the sin-
gle dose studies (n = 4/study), 100mg/kg anakinra (Kineret™,
Amgen, Thousand Oaks, CA) or 2500 IU/kg EPO (Procrit™,
Amgen, ThousandOaks, CA) were administered by subcutaneous
(s.c.) or intraperitoneal injection (i.p.). Blood specimens were
collected from the jugular catheter, immediately prior to the dose,
and at 1, 2, 4, 6, 12, 24, and 30 h. Samples were collected in
microtubes, separated using a centrifuge, and stored at −80◦C
until assayed. The terminal exponential rate constant (β) was
used to determine elimination half-life (T1/2) as 0.693/β. Based
on the single dose pharmacokinetics, the multiple doses were
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calculated to attain clinically relevant steady state concentrations.
Targeted average concentrations of erythropoietin and anakinra
were 5000–10,000mIU/ml and 10–25μg/mL, respectively, based
on clinical studies in non-TBI patients receiving FDA approved
doses. The initial dose was administered i.p. and subsequent doses
administered s.c. every 12 h for 72 h. Blood was collected from
a jugular catheter at 0, 1, 2 and then immediately before and
1 h after injections for 72 h. Serum concentrations were deter-
mined using commercially available ELISA kits (R&D Systems,
Minneapolis, MN).
EXPERIMENTAL INJURY MODEL
All surgeries were performed under aseptic conditions. The CCI
injury model utilized in the present study was based on previ-
ous studies (Anderson et al., 2011, 2013; Peterson et al., 2012).
Animals were anesthetized using a mixture of isoflurane (2–4%)
and oxygen (0.8 L/min). Once the animal was no longer respon-
sive (no ocular or pedal reflexes) the head was shaved and
scrubbed with 70% alcohol followed by betadine and placed into
a stereotaxic device. A midline incision was made through the
skin and the underlying fascia. A circular craniotomy (5.0mm)
was centered 2.4mm posterior to and 2.4mm lateral (left) to
bregma. The contusion injury was created with a sterile stain-
less steel impactor tip (4.0mm in diameter) that was attached
to the Benchmark™ stereotaxic impactor (www.myneurolab.com,
St. Louis, MO). The injury was induced with an impact speed of
3.0m/s and depth of 2.5mm, coming in contact with the dura
for 0.5 s before retraction. To maintain normal body tempera-
ture (37◦C) during surgery and recovery the rats were placed on
a warm water recycling bed and pump system (EZ Anesthesia,
Palmer, PA). Rats receiving sham surgeries underwent identical
surgical preparation as injured animals, with the exception of the
impact (received craniotomies), were sutured, and then trans-
ferred to recovery. The design was completely counter-balanced
to ensure that all animals received the same number of injections,
regardless of treatment condition.
DRUG ADMINISTRATION
Animals were randomly assigned to one of four groups: (a)
Sham, (b) CCI-injured erythropoietin (EPO) 2500 IU/kg (c)
CCI-injured anakinra at 100mg/kg or (d) CCI-injured vehicle.
Based on the results of the pharmacokinetic studies, in order
to obtain peaks concentration within 1–2 h, the initial dose was
administered by i.p. injection and subsequent injections were
administered by s.c. Doses were administered 2 h, 12 h, 24 h, 36 h,
48 h, 60 h, and 72 h after the CCI injury. Both EPO and anakinra
were diluted into 0.9% sterile saline (Sigma Aldrich Co, St. Louis,
MO) such that the amount of fluid per kg body weight was
the same. Blood samples (750μL) were collected in microtubes
from the tail vein 1 h after the final injection, separated using a
microcentrifuge, and stored at−80◦C until assayed. For the func-
tional behavioral studies, a power analysis determined that group
sizes of nine results in a power score >0.85 to detect significant
differences between the groups.
GENE EXPRESSION STUDIES
At specified time point’s post-CCI (24 h, 72 h, and 7 days) 5 intact
sham animals (no craniotomy) and 5 animals in each treatment
group were overdosed with a mixture of CO2 (80%) and O2
(20%). The rats were then decapitated, a cardiac blood sample
collected and brains were rapidly extracted. To maintain quality
control and to assure that all of the brains were injured, each brain
was assigned a rating score (1 = no visual sign of trauma; 2 =
bruised and swollen cortex; 3 = no remaining cortex or exten-
sive damage) (see Figure 1 in Anderson et al., 2011). Only brains
with a score of 2 were used in the subsequent analyses. The brain
was then cut into a 4.0mm coronal slab containing the injury site
in a brain matrix (Braintree Scientific, Inc., Braintree, MA) and
placed onto an RNAase free cold plate. A 5.0mm biopsy punch
was used to collect the injury site and surrounding cortical tis-
sue (Hoane et al., 2006; Anderson et al., 2011). The tissue punch
included all injured cortical tissue and a small strip of pericon-
tusional tissue, with the ventral extent of the punch extending to
the corpus callosum. Tissue punches were placed into microcen-
trifuge tubes, snap frozen and then stored at −80◦C. All samples
were shipped by overnight carrier to the University ofWashington
on dry ice.
Processing of the RNA samples, hybridization to the microar-
ray, scanning with the AffymetrixGeneChip® 3000 scanner and
univariate analysis of the data using various Bioconductor
packages were performed as previously described (Anderson
et al., 2011, 2013). Venn diagrams were generated with the
Bioconductor limma package. Ingenuity Pathway Analysis (IPA)
(Build 131235; Version 11904312; Database Status 02.20.2012;
www.ingenuity.com) was used to analyze differentially expressed
genes (>1.5-fold up or down-regulated, p < 0.05) using the Core
Analysis feature. IPA is a commercial tool that is based on a pro-
prietary database (http://www.ingenuity.com/) to facilitate the
identification of biological themes in microarray gene expres-
sion data. IPA maps the rat genes to their human orthologs and
uses the human orthologs in its pathway analysis. IPA uses a
Right-tailed Fisher’s exact test to determine the probability that
the number of genes annotated to a given biological function,
canonical pathway or transcriptional network in the set of sig-
nificant genes is due to chance alone. The validation of the data
obtained with the microarrays was performed using fluorogenic
5′-nuclease-based assay and quantitative RT-PCR as previously
described (Anderson et al., 2011, 2013). The RT-PCR data was
normalized to the housekeeping gene, β-actin.
FUNCTIONAL BEHAVIORAL STUDIES
Sensorimotor/motor assessment
Locomotor placing task. To assess recovery of coordinated, loco-
motor limb movement, this test was administered on days 2,
4, 6, 8, and 10 post-CCI following methods outlined in previ-
ous studies (Hoane et al., 2008b; Goffus et al., 2010; Peterson
et al., 2012). Rats were pre-tested to establish baseline levels for
2 days before surgery. On each test day, the rat was placed on
an elevated grid floor (56.0 × 54.0 cm) with openings measur-
ing 3.2 × 3.2 cm in size and allowed to freely explore for 120 s.
A “foot-fault” occurred when a rat inaccurately placed a limb
through one of these openings. Total movement on the grid as
measured by the number of lines crossed as well as foot-faults for
each limb was recorded. Rats were administered one trial each
test day. The total number of foot-faults for the limb contralateral
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to the injury was the primary dependent variable of interest.
The following equation was used to calculate the foot faults as
a function of total movement on the grid: (Right forelimb faults -
Left forelimb faults)/lines crossed.
Rotorod. Automated ROTOR-ROD™ (San Diego Instruments,
San Diego, CA) testing was performed on post-injury days 8–12
to assess gross motor coordination. Two days of training occurred
prior to surgery to establish a pre-injury baseline on the rotorod.
Animals were placed on the rotating cylinder (7 cm diameter)
against the rotation and the latency to fall (1.3m) was recorded.
On the first day of training, animals received one training trial
where they were placed on the cylinder, which was stationary,
and replaced when they fell, until they were able to remain on
the cylinder for 60 consecutive seconds so that they become accli-
mated to the device. Following this trial and on all other days of
training, the trial was terminated and the latency was recorded
when the animal fell off of the cylinder. The initial speed of 5 rpm
was maintained for 15 s to allow experimenters to load the rat.
Following this 15 s, the speed of the rotation increased from 5 to
50 rpm over the course of 300 s (acceleration rate of 0.15 rpm/s).
An infrared beam sensor located below the cylinder recorded the
latency for the animal to fall. Each animal received four trials each
day with a 15min inter-trial interval.
Cognitive assessment
Morris water maze (MWM)—reference memory task. All ani-
mals were tested in the MWM using a reference memory
paradigm which has been widely utilized to assess cognitive per-
formance following TBI (Lindner et al., 1998; Hoane et al., 2003,
2006; Vonder Haar et al., 2011; Peterson et al., 2012). The appa-
ratus consisted of a circular, 180 cm diameter blue plastic pool
partially filled with water (22◦C) to a depth of approximately
32 cm. A clear plastic platform (10 × 10 cm) was submerged
approximately 2 cm below the surface located in the northeast
quadrant of the pool for the entirety of the referencememory test-
ing sessions. The animal’s progress on the task was evaluated by a
video camera affixed above the pool and this data was processed
using computer software SMART (San Diego Instruments, San
Diego, CA). Animals were assessed on the acquisition of a refer-
ence memory task beginning on day 14 post-CCI and were tested
for 4 subsequent days. On each testing day, animals received four
trials to locate the submerged platform in the pool, starting at one
of four release points in random order. The trial was terminated
when the rat reached the submerged platform in the northeast
quadrant or when 90 s had elapsed. Latencies were recorded, aver-
aged and used as the main dependent variable. If the rat did not
find the platform within the 90 s, it was guided to the platform
and remained on it for at least 10 s. Each rat remained on the plat-
form for 10 s, after which it was placed in a warm holding cage for
at least 15min before the next trial.
MWM—working memory task. Animals were tested on days
21–23 post-CCI using established methods (Lindner et al., 1998;
Hoane et al., 2003, 2006; Vonder Haar et al., 2011; Peterson et al.,
2012). The procedure was the same as above, except the platform
was submerged at the center of a new randomly chosen quadrant
(south-west, north-west, and south-east) each day. Each animal
was given four trials per day, starting from one of four randomly
chosen release points (inter-trial interval was 15min). The first
trial on each of these days was considered an information trial
and was not included in subsequent analyses; the latencies from
the last three trials were averaged to form a score for the day. Each
trial was terminated when the animal located the platform, or
when 90 s had elapsed. Animals not reaching the platform were
guided to the platform after the trial ended.
Lesion analysis
At 30 days post-CCI, the rats were euthanized with Euthasol
(Virbac Animal Health; 0.3mL i.p.) and transcardially perfused
with 0.9% phosphate-buffered saline (PBS), followed by 10%
phosphate buffered formalin (PBF). Brains were post-fixed in PBF
for 2 days following removal from the cranium. A 30% sucrose
solution was used to cryopreserve the brains 3 days prior to
frozen sectioning. Serial, coronal sections (40μm thickness) were
sliced using a sliding microtome on a frozen stage and collected
into a cryopreservative solution and stored at −20◦C. A series
of sections were brush mounted on gelatin-subbed microscope
slides, stained with cresyl violet, dehydrated, and cover slipped.
The extent of the lesion was analyzed with an Olympus micro-
scope (BX-51) and an Olympus 13.5 megapixel digital camera
(DP-70). Images of sections throughout the extent of the injury
coordinates were captured using the digital capturing system and
area measures of the lesioned tissue were determined using the
ImageJ software package (1.43 u, NIH). The Calvalieri method
was used to calculate the volumes of the ipsilateral cortex and the
contralateral cortex (Coggeshall, 1992; Vonder Haar et al., 2011;
Peterson et al., 2012). Four stereotaxic coordinates throughout
the lesion, at approximately −0.80, −1.80, −2.80, and −3.80mm
relative to bregma, were selected for lesion analysis. The num-
ber of sections and the section thickness (40μm) were multiplied
by the mean area of the remaining cortex. The extent of corti-
cal injury was measured by calculating the percent reduction in
the injured ipsilateral cortex compared to the contralateral cor-
tex at each level using the formula: [1 − (ipsi/contra) × 100] and
which has been shown to be sensitive enough to detect treatment-
induced reductions in injury size (Hoane et al., 2004, 2006, 2008a,
2009).
Data analysis
Behavioral data was analyzed using a mixed model facto-
rial ANOVA and histological data was analyzed using a one-
way between-subjects ANOVA (SPSS v. 15 for Windows). The
between factor of Treatment (EPO-treated, anakinra-treated,
vehicle-injured, and sham) and the within-group factor was day
of testing. Both the main effects and the interaction effects
were considered. Huynh-Feldt corrections and Tukey’s Honestly
Significant Different test (Tukey’s HSD) were used to control for
Type I error in the repeated measures and post-hoc means com-
parison, respectively. A significant level of p = 0.05 was used
for all statistical analyses. A One-Way ANOVA was completed
where the between-subject factor of Treatment (EPO-treated,
anakinra-treated, vehicle-injured, and sham) was used to analyze
the anatomical data. Tukey’s HSD was used to control for Type I
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error and a significant level of p ≤ 0.05 was used for all statistical
analyses. Inter-rater reliability measures were evaluated using the
bivariate correlation of scores obtained between the two raters.
A power analysis indicated that n = 10 for the behavioral studies
would give a power rating of 90% and that n = 5 for the phar-
macokinetic and molecular studies would also allow for detection
of significant differences (Anderson et al., 2013). The evaluators
were blinded to the treatment assignment.
RESULTS
ANAKINRA AND ERYTHROPOIETIN PHARMACOKINETICS
In the non-injured animals, a single dose i.p. or s.c. injection
of EPO 2500 IU/kg, resulted in peak concentrations of 4481 ±
1436mIU/mL and 2086 ± 201mIU/mL at 2 and 24 h, respec-
tively. Due to the prolonged absorption from the s.c. dose, the
apparent T1/2 (mean ± standard deviation) was 16.9 ± 2.6 h
compared to 8.9 ± 0.8 h after i.p. Anakinra 100mg/kg admin-
istered i.p. produced peak concentrations of 62.1 ± 31.7μg/mL
at 1 h post-dose with a T1/2 of 1.8 ± 0.4 h. When adminis-
tered s.c., anakinra peak concentrations of 23.5 ± 2.9μg/mL
occurred 2 h post-dose. Therefore, multiple doses, with the ini-
tial dose by i.p. followed by s.c. every 12 h, resulted in clin-
ically relevant EPO concentrations with minimal fluctuations
with peak and trough concentrations of 13,375 ± 1411mIU/mL
and 13,395 ± 1436mIU/mL, respectively (Figure 1A). Multiple
doses of anakinra produced an initial peak concentration of
51.9 ± 23.6μg/mL and then average plasma concentrations of
20.3 ± 6.9μg/mL (Figure 1B). In the functional behavioral and
gene expression studies, the EPO and anakinra serum concentra-
tions were 9990 ± 1054mIU/mL and 9127 ± 944mIU/mL and
40 ± 7μg/mL and 28 ± 14μg/mL when sampled 72 h post-CC,
respectively.
FUNCTIONAL BEHAVIORAL STUDY
In the Locomotor placing task, foot faults score was used as
the primary dependent variable (Figure 2A). The within-subjects
factor of Day (2, 4 6, 8, and 10) and the between-subjects fac-
tor of Treatment (EPO-treated, anakinra-treated, vehicle-injured,
and sham) were significant. The interaction of Day × Treatment
was significant [F(12, 168) = 2.32, p < 0.05]. Both the main effect
of Day [F(4, 168) = 4.39, p < 0.05] and Treatment [F(3, 42) =
106.71, p < 0.001] were significant. The sham group performed
significantly better than the EPO-treated group [HSD(19) = 3.37,
p < 0.05], the anakinra-treated group [HSD(19) = 4.09, p <
0.05], and the vehicle-injured group [HSD(22) = 4.19, p < 0.05].
There were no significant differences between either of the drug
treatment groups and the vehicle-injured group.
On the Rotor-Rod, the latency to fall off the rotating cylin-
der was averaged over the four trials for each testing day and
used as the dependent variable to measure gross motor func-
tion with the within-subjects factor of Day (8–12) and the
between-subjects factor of Treatment (EPO-treated, anakinra-
treated, vehicle-injured, and sham). The interaction of Day ×
Treatment was not significant [F(11.68, 163.50) = 8.28, p = 0.830].
Both the main effect of Day [F(3.893, 163.5) = 10.75, p < 0.001]
and Treatment [F(3, 42) = 3.98, p < 0.05] were significant, see
Figure 2B. The sham group performed significantly better
FIGURE 1 | Concentration-time curves after administration of (A) EPO
2500mg/kg i.p. for the first dose, followed by s.c. every 12 h and (B)
anakinra 100mg/kg i.p. for the first dose, followed by s.c. every 12 h.
than the EPO-treated group [HSD(19) = 41.23, p < 0.05], the
anakinra-treated group [HSD(19) = 37.59, p < 0.05], and the
vehicle-injured group [HSD(22) = 41.68, p < 0.05]. There were
no significant differences between either of the drug treatment
groups and the vehicle-injured group.
In the reference memory task, the latency to reach the
platform was averaged over the four trials for each testing
day during reference memory acquisition (Figure 3A), with the
within-subjects factor of Day (14–17) and the between-subjects
factor of Treatment (EPO-treated, anakinra-treated, vehicle-
injured, and sham). The interaction of Day × Treatment was
not significant [F(9, 120) = 0.50, p = 0.87]. Both the main effect
of Day [F(3, 120) = 35.14, p < 0.001] and Treatment [F(3, 40) =
5.03, p < 0.05] were significant. The sham group performed sig-
nificantly better than the EPO-treated group [HSD(19) = 27.08,
p < 0.05], the anakinra-treated group [HSD(19) = 20.64, p <
0.05], and the vehicle-injured group, [HSD(22) = 21.11, p <
0.05]. There were no significant differences between either of the
drug treatment groups and the vehicle-injured group.
In the working memory task, the latency to reach the platform
was averaged over the last three trials for each testing day
during working memory acquisition, with the within-subjects
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FIGURE 2 | Sensorimotor Assessment. (A) The Locomotor Placing task
showing the average fault scores (+SEM) for days 2, 4, 6, 8, and 10
post-CCI. No significant differences between the treated animals and
vehicle were found. A trend toward worsening was seen in the
anakinra-treated group. (B) The Rotorod test showing the average latency
to fall (+SEM) off of the rotating cylinder for day’s 8–12 post-CCI. No
significant differences between the treated animals and vehicle were
found.
FIGURE 3 | Cognitive assessment. (A) The MWM reference memory task
showing the average latency (+SEM) to reach the platform on day’s 14–17
post-CCI. No significant differences between the treated animals and vehicle
were found. (B) The MWM working memory task showing the average
latency (+SEM) to reach the platform on day’s 21–23 post-CCI. No significant
differences between the treated animals and vehicle were found.
factor of Day (21–23) and the between-subjects factor of
Treatment (EPO-treated, anakinra-treated, vehicle-injured, and
sham), see Figure 3B. The interaction of Day × Treatment was
not significant [F(6, 80) = 1.26, p = 0.291]. The main effect of
Day [F(2, 80) = 2.07, p = 0.131] was not significant, but the
main effect of Treatment [F(3, 40) = 9.57, p < 0.001] was signif-
icant. The sham group performed significantly better than the
EPO-treated group [HSD(19) = 22.13, p < 0.001], the anakinra-
treated group [HSD(19) = 22.89, p < 0.001], and the vehicle-
injured group [HSD(22) = 18.74, p < 0.001]. There were no
significant differences between either of the drug treatment
groups and the vehicle-injured group.
LESION ANALYSIS
The ratio of lesion volume in the cortices, hippocampus, and
hemisphere for each group were each compared with a one-way
ANOVA [Group (EPO-treated, anakinra-treated, vehicle-injured,
and sham)], see Figure 4A. There was a significant differ-
ence between the groups [F(3, 35) = 42.13, p < 0.001] for lesion
volume in the cortices. Post-hoc analysis showed that the
sham group had significantly more cortical volume compared
to the EPO-treated group [HSD(19) = 29.56, p < 0.001], the
anakinra-treated group [HSD(19) = 28.87, p < 0.001], and the
vehicle group [HSD(22) = 29.65, p < 0.001]. There were no sig-
nificant differences between either of the drug treatment groups
and the vehicle-injured group.
There was a significant difference between the groups
[F(3, 35) = 11.19, p < 0.001] for lesion volume in the hip-
pocampus. Post-hoc analysis showed that the sham group had
significantly more hippocampal volume compared to the EPO-
treated group [HSD(19) = 32.22, p < 0.05], the anakinra-treated
group [HSD(19) = 41.59, p < 0.001], and the vehicle group
[HSD(22) = 45.82, p < 0.001]. There were no significant dif-
ferences between either of the drug treatment groups and the
vehicle-injured group.
There was a significant difference between the groups
[F(3, 35) = 11.9, p < 0.001] for lesion volume in the hemispheres.
Post-hoc analysis showed that the sham group had significantly
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FIGURE 4 | Lesion Analysis. (A) The average (+SEM) percent reduction in
hemispherical, cortical, and hippocampal volumes between the ipsilateral and
contralateral sides of the injury. No significant differences between the
treated animals and vehicle were found. (B) Representative images of cresyl
violet stained tissue throughout the injury coordinates; −0.08mm, −1.8mm,
−2.8mm, and −3.8mm, relative to bregma. Scale bar = 2.0mm.
more hemispherical volume compared to the EPO-treated
group [HSD(19) = 16.55, p < 0.001], the anakinra-treated group
[HSD(19) = 18.35, p < 0.001], and the vehicle group [HSD(22) =
19.75, p < 0.001], see Figure 4. There were no significant dif-
ferences between either of the drug treatment groups and the
vehicle-injured group. See Figure 4B for representative lesion
images for the experimental groups.
GENE EXPRESSION
The microarray data passed all the standard and advanced qual-
ity control metrics. The number of differentially expressed genes
(>1.5-fold change, p < 0.05) at 24 h, 72 h and 7 days are pre-
sented in Table 1. The vehicle to sham comparison reflects the
effect of the TBI without treatment relative to sham controls. The
EPO or anakinra (CCI animals that received treatment) to vehi-
cle (CCI animals that received vehicle) comparison evaluates the
effect of treatment on gene expression in the context of TBI. Both
EPO and anakinra treatments resulted in significant changes in
brain gene expression in the CCI model demonstrating accept-
able brain penetration. At all three time points, EPO treatment
resulted in significantly more differentially expressed genes than
anakinra. At 7 days post-injury (4 days after the last dose of EPO
or anakinra), 337 genes were differentially expressed by EPO with
96% (322/337) showing increased expression. Similarly, at 7 day
post injury, 209 gene were differentially expressed by anakinra
with 85% of genes (178/209) showing increased expression. The
Venn diagrams in Figure 5 show the number of differentially
expressed genes (1.5-fold, p < 0.05) that are unique for each
of the EPO/vehicle and ankinra/vehicle contrasts, as well as the
number of genes that are shared between these contrasts for each
of the three time points. At 24 h and 7 days post-TBI, approxi-
mately a quarter of the genes differentially expressed with EPO
treatment also were affected by anakinra treatment. At 72 h post-
TBI, only 8 (3%) of the 58 genes differentially expressed by
anakinra treatment compared to vehicle were also differentially
expressed with EPO treatment.
Ingenuity Pathway Analysis (IPA) was used to facilitate the
identification of biological themes in the microarray data. IPA
shifts the emphasis from the evaluation of single genes to an
Table 1 | The number of differentially expressed genes probes
(>1.5-fold up or down, p < 0.05).
24 h 72 h 7 days
Down Up Total Down Up Total Down Up Total
Vehicle/Sham 1014 1457 2471 1330 1956 3286 318 1104 1422
EPO/Vehicle 137 58 195 178 47 245 15 322 337
Anakinra/Vehicle 103 17 120 33 25 58 31 178 209
FIGURE 5 | The Venn diagrams show the number of genes whose
expression was up or down regulated more than 1.5-fold (p < 0.05) in
the EPO/Vehicle and Anakinra/Vehicle contrasts at the 24h, 72h, and
7 day time points. Venn diagrams were generated with the
Bioconductorlimma package.
evaluation of molecular pathways, networks and biological func-
tions. Functional categories are identified by molecular and cel-
lular functions. For anakinra at 24 h and EPO at all three times
points, the regulated genes in the top 3 functional categories were
involved in cellular movement (primarily inflammatory cells),
inflammatory response and cell-to-cell signaling. For anakinra,
at 7 d post-TBI, the top functional categories were molecular
transport, organismal injury and abnormalities and carbohy-
drate metabolism. Differentially expressed genes of interest were
selected and their specific fold changes in expression for the con-
trast EPO/vehicle, anakinra/vehicle and vehicle/shame are pre-
sented in Table 2. Of note, IL 1b, IL 1 receptor, type II, IL 1
receptor antagonist (IL-1rn), several chemokines and chemokine
receptors and nitric oxide synthase were significantly increased
by TBI and decreased by both EPO and anakinra. Specifically,
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Table 2 | The effect of Erythropoietin, Anakinra and TBI (vehicle/sham) on genes of interest (1.5 fold change, p < 0.05).
Affymetrix ID Gene symbol Genes EPO vehicle Anakinra vehicle Vehicle sham
24 H
10775968 Alb Albumin 1.91 n.s. 0.50
10911380 Aldh1a2 Aldehyde dehydrogenase 1 family, member A2 1.97 n.s. n.s.
10744425 Alox15 Arachidonate 15-lipoxygenase 3.76 1.95 n.s.
10821016 Ccnb1 Cyclin B1 1.50 n.s. n.s.
10717195 Ccnb2 Cyclin B2 1.53 n.s. n.s.
10921163 Ccr1 Chemokine (C-C motif) receptor 1 0.49 0.59 9.78
10829761 Cdk1 Cyclin-dependent kinase 1 1.50 n.s. 2.36
10775896 Cxcl3 Chemokine (C-X-C motif) ligand 2 0.48 n.s. 11.92
10924245 Cxcr2 Chemokines (C-X-C motif) receptor 2 0.49 0.47 18.82
10825153 Fcgr1a Fc fragment of IgG, high affinity Ia, receptor 0.66 n.s. 7.36
10755148 Fetub Fetuin B n.s. 0.64 2.48
10926967 Gsta2 Glutathione-S-transferase alpha 2 1.56 n.s. 0.42
10849841 IL1b Interleukin 1 beta 0.48 0.59 6.82
10922816 IL1r2 Interleukin 1 receptor, type II 0.53 0.64 7.10
10834109 IL1rn Interleukin 1 receptor antagonist 0.46 0.59 17.23
10922882 IL18rap Interleukin 18 receptor accessory protein 0.64 0.66 2.38
10907689 Itga5 Integrin, alpha 5 0.66 n.s. 4.63
10711299 Itgax Integrin, alpha X 0.61 0.44 4.35
10810736 Lcat Lecithin cholesterol acyltransferase 1.55 n.s. 0.44
10736312 Nos2 Nitric oxide synthase 2, inducible 0.42 0.51 7.71
10873341 Pla2g2a Phospholipase A2, group IIA n.s. 1.77 2.23
10708214 Prc1 Protein regulator of cytokinesis 1 1.52 1.64 1.54
10835817 Ptgs1 Prostaglandin-endoperoxide synthase 1 n.s. 1.52 n.s.
10764551 Ptgs2 Prostaglandin-endoperoxide synthase 2 0.56 n.s. 2.67
10742194 Pttg1 Pituitary tumor-transforming 1 1.57 n.s. n.s.
10738130 Rara Retinoic acid receptor, alpha 0.66 n.s. 1.83
10786108 Rarb Retinoic acid receptor, beta 1.94 n.s. 0.25
10827686 RT1-M6-1 RT1 class I, locus M6, gene 1 0.46 n.s. 2.13
10827691 RT1-M6-2 RT1 class I, locus M6, gene 2 0.48 n.s. 2.21
10817071 S100a8 S100 calcium binding protein A8 n.s. 0.66 3.28
10934608 Tir13 Toll-like receptor 13 0.64 0.17 6.31
10770577 Tgfb2 Transforming growth factor, beta 2 0.63 n.s. n.s.
10746976 Top2a Topoisomerase (DNA) II alpha 1.50 n.s. 3.26
72 H
10885393 Akap5 A kinase (PRKA) anchor protein 5 1.54 n.s. 0.57
10932912 Alas2 Aminolevulinate, delta-, synthase 2 2.96 1.87 n.s.
10744425 Alox15 Arachidonate 15-lipoxygenase 14.84 1.75 n.s.
10736697 Ccl2 Chemokines (C-C motif) ligand 2 0.66 n.s. 45.91
10736702 Ccl7 Chemokines (C-C motif) ligand 7 0.52 n.s. 9.29
10858566 Clec4a2 C-type lectin domain family 4, member A2 0.61 n.s. 7.66
10866019 Clec7a C-type lectin domain family 7, member A 0.59 n.s. 30.82
10914614 Ccr2 Chemokine (C-C motif) receptor 2 0.51 n.s. 11.00
10865585 Cd4 Cd4 molecule 0.53 n.s. 2.86
10856274 Cd8a CD8a molecule 0.57 n.s. 5.90
10856265 Cd8b CD8b molecule 0.56 n.s. 5.85
10802013 Cd72 Cd74 molecule, major histocompatibility
complex, class II invariant chain
0.64 n.s. 3.93
10897428 Csf2rb Colony stimulating factor 2 receptor, beta,
low-affinity (granulocyte-macrophage)
0.60 n.s. 10.88
10767373 Cxcr4 Chemokine (C-X-C motif) receptor 4 0.63 n.s. 2.65
10811571 Cyba Cytochrome b-245, alpha polypeptide 0.66 n.s. 3.95
(Continued)
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Table 2 | Continued
Affymetrix ID Gene symbol Genes EPO vehicle Anakinra vehicle Vehicle sham
10936899 Cybb Cytochrome b-245, beta polypeptide 0.65 n.s. 17.68
10732652 Dusp1 Dual specificity phosphatase 1 n.s. 1.51 0.40
10828344 HLA-DRAa Major histocompatibility complex, class II, DR
alpha
0.55 0.65 7.18
10831657 HLA-DRB1a Major histocompatibility complex, class II, DR
beta 1
0.63 0.69 2.50
10828351 HLA-DQA1a Major histocompatibility complex, class II, DQ
alpha 1
0.60 0.71 3.92
10767518 Ikbke Inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase epsilon
0.66 n.s. 2.30
10834109 ILr1n Interleukin 1 receptor antagonist 0.55 n.s. 9.09
10938654 IL2rg Interleukin 2 receptor, gamma 0.65 n.s. 4.34
10832306 Itgb2 Integrin, beta 2 0.65 n.s. 7.52
10907689 Itgb5 Integrin, alpha 5 (fibronectin receptor, alpha
polypeptide)
0.60 n.s. 4.13
10907881 Mmp3 Matrix metallopeptidase 3 0.43 0.51 3.22
10780205 Mmp14 Matrix metallopeptidase 14
(membrane-inserted)
0.61 n.s. 2.66
10796476 Mrc1 Mannose receptor, C type 1 0.63 n.s. 4.64
10757898 Ncf1 Neutrophil cytosolic factor 1 0.60 n.s. 6.81
10764722 Ncf2 Neutrophil cytosolic factor 2 0.65 n.s. 4.32
10873336 Pla2g2a Phospholipase A2, group IID 0.54 n.s. 4.76
10828351 RT1-Ba RT1 class II, locus Ba 0.60 n.s. 3.92
10831557 RT1-Db1 RT1 class II, locus Db1 0.63 n.s. 2.50
10797509 Syk Spleen tyrosine kinase 0.66 n.s. 4.14
7 DAYS
10819379 Adh1ca Alcohol dehydrogenase (class 1) 1.64 n.s 1.61
10854406 Akr1b10a Aldo-ketoreductase family 1, member B10 1.90 n.s. n.s.
10911380 Aldh1a2 Aldehyde dehydrogenase 1 family, member A2 1.81 n.s. 1.61
10722992 Anpep Alanyl (membrane) aminopeptidase 2.44 n.s. 2.74
10744425 Alox15 Arachidonate 15-lipoxygenase 18.75 n.s. n.s.
10719524 Apolipoprotein C-I (Apoc1) 1.69 n.s. n.s.
10848030 Bbox1 Butyrobetaine (gamma), 2-oxoglutarate
dioxygenase 1
n.s. 1.61 n.s.
10914614 Ccr2 Chemokine (C-C motif) receptor 2 n.s. 0.63 n.s.
10803991 Cd14 CD14 molecule 1.59 n.s. 2.06
10940473 Cd36 CD36 molecule (thrombospondin receptor) 3.97 n.s. 2.62
10935177 Cldn2 Claudin 2 3.27 3.85 0.19
10767373 Cxcr4 Chemokine (C-X-C motif) receptor 4 1.51 n.s. n.s.
10936899 Cybb Cytochrome b-245, beta polypeptide 1.65 n.s. 10.08
10765212 F5 Coagulation factor V (proaccelerin, labile factor) 2.22 3.03 0.46
10794734 F13a1 Coagulation factor XIII, A1 polypeptide 2.00 n.s. n.s.
10810778 Dpep2 Dipeptidase 2 1.67 n.s. 1.84
10928761 Fn1 Fibronectin 1 2.37 n.s. 2.23
10939901 Gpr101 G protein-coupled receptor 101 (Gpr101) n.s. 1.83 0.54
10804221 Gpr151 G protein-coupled receptor 151 n.s. 1.82 n.s.
10825915 Gstm2 Glutathione S-transferase mu 2 1.78 n.s. n.s.
10806122 Hmox1 Hemeoxygenase (decycling) 1 1.98 n.s. 5.90
10937302 Htr2c 5-hydroxytryptamine (serotonin) receptor 2C 1.90 0.46
10841693 Lbp Lipopolysaccharide binding protein 2.19 n.s. 1.94
10791250 Lpl Lipoprotein lipase 1.55 1.71 0.56
10874918 Ly96 Lymphocyte antigen 96 1.51 n.s. 2.63
10859392 Mgst1 Microsomal glutathione S-transferase 1 1.67 n.s. 1.72
(Continued)
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Table 2 | Continued
Affymetrix ID Gene symbol Genes EPO vehicle Anakinra vehicle Vehicle sham
10842239 Mmp9 Matrix metallopeptidase 9 1.85 n.s. n.s.
10907869 Mmp12 Matrix metallopeptidase 12 1.91 n.s. 5.62
10780205 Mmp14 Matrix metallopeptidase 14
(membrane-inserted)
1.60 n.s. 1.79
10893231 Mmp19 Matrix metallopeptidase 19 1.51 n.s. 2.91
10788427 Msr1a Macrophage scavenger receptor 1 2.53 n.s. 3.36
10821698 Osmr OncostatinM receptor 1.51 n.s. 3.69
10860867 Pon1 Paraoxonase 1 3.55 3.53 n.s.
10860878 Pon3 Paraoxonase 3 1.79 n.s. n.s.
10873341 Pla2g2a Phospholipase A2, group IIA 1.61 n.s. n.s.
10873336 Pla2g2d Phospholipase A2, group IID 2.17 n.s. n.s.
10751295 Pla1a Phospholipase A1 member A 1.70 n.s. 1.68
10782271 Plau Plasminogen activator, urokinase 1.70 n.s. 4.36
10823819 Rxfp1 Relaxin/insulin-like family peptide receptor 1 n.s. 0.62 n.s.
10912439 Rbp1 Retinol binding protein 1, cellular 1.81 n.s. 1.54
10761047 Serpine1 Serpin peptidase inhibitor, clade E, member 1 2.71 n.s. n.s.
10819139 Tacr3 Tachykinin receptor 3 0.56 0.62 n.s.
aA rat gene symbol was not provided by the Affymetrix annotation file for this transcript, however, IPA identified a human ortholog. Therefore, the gene symbol for
the human ortholog is listed here.
administration of anakinra decreased gene expression of endoge-
nous IL-1rn only at the 24 h with no effect at 72 h or 7 days and
EPO decreased the gene expression of IL-1rn at both 24 and 72 h
post-injury.
AT 7 d post-TBI, anakinra increased the expression of
several receptors involved in signaling pathways including
5-hydroxytryptamine (serotonin) receptor 2c, cholinergic recep-
tor, nicotinic, alpha 3, fibroblast growth factor, G-protein-
coupled receptor 101 and 105 and prolactin receptor (Table 2).
EPO treatment caused an over expression of genes involved in the
coagulation system (coagulation factor V (F5), coagulation factor
XIII, A1 polypeptide, plasminogen activator, urokinraase and ser-
pin peptidase inhibitor, clade E) and expression of genes involved
in acute phase response signaling (hemeoxygenase 1, fibronectin
1, oncostatin M receptor, lipopolysaccharide binding protein, ser-
pin peptidase inhibitor member 1 and retinal binding protein 1)
(Table 2).
We used TaqMan-based quantitative-PCR (qPCR) analysis to
validate gene expression changes of 14 genes (Alox15, Casp12,
CD68, CYP1B1, GAL, HMOX1, IHF2, IL1r2, IL1rn, MDK,
MMP9, NIACR1, S100A9, XDH) selected from specific path-
ways of interest in TBI. The data generated via microarray and
quantitative-PCR (qPCR) was normalized to β-actin. Figure 6
shows that the qPCR findings were highly correlated with the
microarray data (Slope = 1.352, Pearson’s R = 0.859).
DISCUSSION
The dosage regiment used in our studies of anakinra and EPO
were designed to produce concentrations in the range reported
in patients receiving FDA approved doses and to reflect initiating
therapy within 4 h of a head injury in patient. Clinically, admin-
istering an intravenous (i.v.) loading dose of either drug results
in rapid peak concentrations, compared to the delay in peak
FIGURE 6 | TaqMan based RT-PCR validation of the microarray data for
the selected genes: Alox15 (arachidonate 15-lipoxygenase), Casp12
(caspase 12), CD68 (CD 68 molecule), Cyp1b1 (cytochrome P450 1b1),
Gal (galanin), Hmox1 (hemeoxygenase 1), IGF2 (insulin like growth
factor 2), IL1rn (interleukin 1 receptor antagonist), Mdk (midkine),
Mmp9 (matrix metallopeptidase 9), Niacr1 (niacin receptor 1), S100a9
(S100 calcium binding protein A9), Xdh (xanthine dehydrogenase). The
RT-PCR data was normalized to the housekeeping gene β-actin. Pearson’s
coefficient, r = 0.859.
found with our experimental model (i.p) initiated 2 h post-TBI.
The FDA approved dosage recommendations for EPO is 150U/kg
administered s.c. three times weekly or 40,000U weekly. EPO at
a dose of 40,000 (∼500 IU/kg) proposed for use in critically ill
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patients (Corwin et al., 2002) and TBI patients (Nirula et al.,
2010) when administered i.v. would result in an peak concentra-
tion of approximately 10,000mIU/ml with an average elimination
half-life of 17 h and reaching non-detectable concentrations by
3 days post-dose (McCluskey et al., 2009). The recommended
dose of anakinra in rheumatoid arthritis is 100mg/day admin-
istered s.c. A pilot study of anakinra in acute stroke patients,
receiving 100mg i.v. bolus followed by a 2mg/kg·h infusion
resulted in median concentrations ranging from 20 to 40μg/mL
(Emsley et al., 2005).
The immunomodulation effects of EPO and anakinra did not
translate into effects on functional behavioral and lesion stud-
ies. The severities of these deficits were similar to what we have
observed using this model of injury previously (Kuypers and
Hoane, 2010; Swan et al., 2011; Vonder Haar et al., 2011; Peterson
et al., 2012). Treatment with either EPO or anakinra failed to
induce significant beneficial effects on recovery of function in all
four behavioral tests examined in this study. Additionally, both
drugs failed to produce any significant effects on the prevention
of injury induced tissue loss in the cortex or hippocampus when
examined 30 days post-injury.
The use of microarray analysis to delineate gene expression
patterns and profile changes is a powerful tool that can be used to
evaluate the potential effect of treatment, in addition to increasing
the understanding of the mechanism of the treatment effect. Both
EPO and anakinra treatments penetrated the brain and altered the
inflammatory and immune pathways.
The lack of effect of EPO and anakinra on functional recovery
of cognition and motor behavior is in contrast to the signifi-
cant effect of other drugs such as progesterone and nicotinamide
when administered for 72 h in the same CCI model (Peterson
et al., 2012). Both nicotinamide and progesterone treatments also
resulted in significant effects on the expression of genes involved
in the inflammatory/immune pathways (Anderson et al., 2011,
2013). However, in contrast to EPO and anakinra, both nicoti-
namide and progesterone also demonstrate significant effects on
gene expression of other biological pathways (Anderson et al.,
2011). Nicotinamide treatment resulted in the differential expres-
sion of genes involved in the inflammatory/immune pathways
only at 24 h and not at 72 h and 7 days with IPA analysis also
identified over-expression of genes involved in 1L-10 signaling,
LXR-RXR activation, TREM1 signaling, communication between
innate and adaptive immune cells and PPAR signaling. However,
the canonical pathways identified at 72 h after injury for nicoti-
namide included a significant effect on cell signaling pathways
involving neurotransmitters, neuropeptides, growth factors and
ion channels (Anderson et al., 2013). In addition to positive
and negative effects on inflammatory pathways, progesterone
also affected genes involved in cell proliferation, DNA damage
response, regulation of apoptosis and blood vessel remodeling
(Anderson et al., 2011).
EPO significantly increased the gene expression of arachido-
nate 15-lipoxygenase (Alox15) at 24 h, 72 h and 7 days post-TBI
and anakinra increased the expression of Alox15 at 24 and 72 h
post-TBI. Alox15 is considered to have a pro-inflammatory effect
and may play a key role in the acute inflammatory response
and reportedly leads to the generation of unstable lipid products
from arachidonate (Kuhn and O’Donnell, 2006). Previous stud-
ies investigating the effect of two different doses of progesterone
(Anderson et al., 2011) and nicotinamide (Anderson et al.,
2013) on gene expression in the CCI model found that neither
nicotinamide infusion nor low dose progesterone increased
Alox15. In contrast, the higher dose of progesterone did signif-
icantly increase gene expression of Alox15. When low and high
dose progesterone and nicotinamide were compared on the func-
tional recovery of cognitive behavior in the same model, the low
dose progesterone and nicotinamide produced significant effects
on functional recovery that were not found with the higher dose.
Nicotinamide and low dose progesterone also reduced tissue loss
compared to vehicle (Peterson et al., 2012). As high concentra-
tions of IL-1ra are associated with better outcome in patients
(Hutchinson et al., 2007), the decreased gene expression of IL-
1rn by EPO at 24 and 72 h and by anakinra at 24 h post-TBI
may also be a significant negative effect of the treatment. Both
doses of progesterone increased IL-1rn at 72 h (Anderson et al.,
2011). Nicotinamide did decrease gene expression of IL-1rn at
24 h with no effect at 72 h or 7 days post-injury (Anderson et al.,
2013).
The majority of the pre-clinical research in animal mod-
els evaluating the effectiveness of EPO in brain injury utilized
a dose of 5000U/kg, which was tested at various time-points
ranging from a pretreatment up to 9 h post-injury, with ear-
lier administration resulting in greater benefits (Brines et al.,
2000; Cerami et al., 2002). However, beneficial effects were
found with administration as late as 24 h post-injury (Zhang
et al., 2009; Meng et al., 2011) and with multiple dose studies
administered up to 14 days (Lu et al., 2005; Liao et al., 2008;
Xiong et al., 2008). Meng et al. found dose dependent effects of
EPO when administered i.p. at 24, 48, and 72 h (Meng et al.,
2011). All doses (1000–7000U/kg) provided some neuroprotec-
tion in the form of less hippocampal cell loss and improved
sensorimotor and spatial learning performance in comparison
to the sham group (Meng et al., 2011). However, the opti-
mal dose was 5000U/kg for a significant improvement in both
histological and functional outcomes. This dose would result
in EPO concentration considerably above those associated with
the current FDA recommendations (150U/kg) (Rizzo et al.,
2010).
This study is limited by evaluating only one dosage regiment
initiated at one time point. Experimental studies have demon-
strated both a neurotoxic as well as neuroprotective function of
inflammatory response (Lenzlinger et al., 2001). The response is
pro-inflammatory during the acute phase and anti-inflammatory
during the chronic phase, which theoretically assists in repair and
recovery processes.(Correale and Villa, 2004). Therefore, the tim-
ing of the inflammatory modulator treatment may be critical.
The limited pre-clinical data evaluating IL-1ra in TBI, suggests
that initiating therapy later for anakinra would not increase effi-
cacy, however, increasing the treatment duration could improve
outcome. Treatment of IL-1ra, 100mg/kg s.c. reduced injury vol-
ume by 44% when treated within 15min, but only 28% when
administrated at 4 h in the fluid percussion injury (FPI) model
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(Toulmond and Rothwell, 1995). In the FPI model, when IL-
1ra 100mg/kg was administered 15min after injury and animals
were treated for 7 days, IL-1ra significantly reduced neuronal loss
in the hippocampus and the cortex. A lower dose (10mg/kg)
had no significant effects (Sanderson et al., 1999). As starting
therapy within 15min of a head injury is not feasible, if early
initiation is necessary for effect, anakinra would not provide a
practical treatment. For EPO, initiating therapy at 24 h post-
TBI and treating for a long duration may have improved the
effects.
Anakinra and EPO initiated at dosage regiments designed
to produce concentrations in the range reported in patients
receiving FDA approved doses did result in significant effects
on gene expression in the brain reflecting adequate penetra-
tion and altered genes involved in inflammatory processes;
however, the dose regiments were not sufficient to produce
neurorestorative effects. This data suggests that targeting inflam-
matory processes alone may not be sufficient for prevent-
ing secondary injuries after TBI. Ultimately, a polytherapy
approach that addresses the multitude of immediate and pro-
longed symptoms of TBI may be the key to an effective overall
treatment.
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